Ad copy

I've signed off on too many liver transplant referrals to stay quiet about this. If your GP just told you to "cut back on the drinking and come back in six months," I need to tell you something they're not. I've evaluated more than 3,000 patients for liver disease over 22 years as a board-certified hepatologist. I've signed off on hundreds of transplant referrals and watched dozens of those patients die on the wait list. When a 49-year-old man walks into my office with ALT of 89 and a casual social drinking history, I already know exactly where he's heading if he follows the standard protocol. Eighteen months of "cut back, take milk thistle" with no measurable improvement. Two years before his first Fibroscan shows mild fibrosis. Four years before the fibrosis has progressed to F2. Six years before a biopsy confirms F3-bridging fibrosis. Eight to ten years before he gets the diagnosis nobody comes back from in any meaningful way: cirrhosis. Then hepatocellular carcinoma surveillance every six months. Then ascites. Then the transplant evaluation, which 60% of patients fail to clear. Then the wait list, on which he may or may not survive long enough to receive an organ. Then if he gets the transplant, immunosuppression for the rest of his life and a 75% five-year survival rate at best. I'm Dr. Lucas Pemberton. Board-certified hepatologist. 22 years in practice. I still sign transplant referrals — but only when the cirrhosis is genuinely beyond what intervention could address. Decompensated cirrhosis. End-stage liver failure. Men whose hepatic function is genuinely beyond what regeneration can recover. What I see every day? Men in their 40s and 50s being told to "cut back, take milk thistle, see you in six months" who should have been intervened on aggressively at the first sign of ALT elevation. Men whose fatty liver was reversible at ALT 78 — and isn't anymore three years later because we monitored a number while the underlying hepatic vascular dysfunction kept progressing into fibrosis. And I was part of the system watching them progress. I've been the hepatologist signing off on the "monitor and re-test in six months" plan for 22 years. I've watched thousands of men start with elevated ALT at a routine physical. The GP told them to cut back on drinking and take milk thistle. They cut back — somewhat. They took the milk thistle for three months and stopped. The repeat lab six months later showed ALT roughly the same. The GP said keep cutting back, see me in a year. The next year's lab showed ALT slightly higher. The GP ordered a Fibroscan. The Fibroscan showed F1 mild fibrosis. The patient was now in the hepatology referral pipeline. We added a recommendation to lose weight, stop drinking entirely, control diabetes if present. Two years later, the Fibroscan showed F2. Three more years, F3. A liver biopsy was ordered. Bridging fibrosis with early cirrhotic changes. The diagnosis was now made. The 6-month HCC surveillance started. By year 8 from initial ALT elevation, the patient had compensated cirrhosis. By year 12, decompensated. By year 13, dead — usually of a complication that the death certificate listed under a different name. And I've watched what happens 5, 8, 12 years into that escalation. The 54-year-old who cut back significantly when his ALT first came back at 92. Went from a six-pack on weekends and two beers most weeknights down to one beer with dinner three nights a week. The numbers came down slightly — ALT to 78 from 92 — but didn't normalize. His GP and I both told him to keep cutting back. He couldn't cut more without quitting entirely. He told us he wasn't ready to do that. His ALT stabilized in the 70s. His Fibroscan at year 3 showed F1, year 5 showed F2. He's 57 now. He has compensated fatty liver disease that, by every prognostic model, will progress to cirrhosis within 8-12 years. He did exactly what we asked him to do. The reduction in alcohol intake didn't reverse the underlying inflammation. We never addressed the actual mechanism. The 60-year-old. Moderate drinker for 25 years — three to four drinks most nights, more on weekends. Always considered himself "responsible" — never drove drunk, never missed work. His ALT had been hovering between 80 and 110 for the last six years. His GP and I both told him repeatedly to cut back. He did, sometimes for months at a time. The ALT improved temporarily and then returned. By 60, his Fibroscan showed F3-F4. Biopsy confirmed early cirrhosis. He stopped drinking entirely after the diagnosis. The cirrhosis didn't reverse. His HCC surveillance is now every four months. His MELD score is being monitored monthly. He may need transplant evaluation within 5 years. The 65-year-old. Lifelong moderate drinker. Diagnosed with cirrhosis at 58. Stopped drinking immediately. Did everything his hepatology team asked. At his routine 6-month HCC surveillance ultrasound at age 65, a 4cm lesion was identified in his right lobe. Biopsy confirmed hepatocellular carcinoma. By the time it had grown large enough to detect, it had already invaded the portal vein. He was no longer a transplant candidate. His oncologist tried immunotherapy. He died at 67. I see them in follow-up. They're grateful for the diagnosis and the monitoring. They're grateful for the surveillance that catches HCC early enough to treat, when it's caught early enough. But I know what they lost. They had time, before the fibrosis had progressed, to address the underlying hepatic vascular dysfunction driving their elevated ALT. Years to repair the sinusoidal endothelium instead of just "cutting back" on the input that was overwhelming it. Years to save themselves from the diagnostic cascade that ends in cirrhosis, HCC surveillance, transplant evaluation, and a mortality rate higher than most cancers. Their elevated ALT was giving them a warning the entire time. "Cut back on drinking" just reduced one input — alcohol load — while the underlying hepatic microvascular dysfunction kept progressing. The Kupffer cells inside their livers stayed inflamed. The stellate cells stayed activated. The fibrosis kept building. When my own ALT crossed 78 at age 50, I almost just kept drinking the same way I always had. I'd been doing this for 19 years at that point. I had two drinks most nights with dinner, three or four on weekends. The pattern most of my patients followed. I knew the ALT elevation was a warning. I had given that warning to thousands of patients. I had also watched it not matter — the standard "cut back" protocol didn't reverse the underlying mechanism in the vast majority of my patients, even when they complied. So I went looking for what was actually happening inside hepatic sinusoidal endothelium when alcohol metabolism produces chronic inflammation — and what could potentially repair it. What I found made me furious that I'd been telling men "cut back on the drinking" for two decades without ever telling them what was structurally happening to their hepatic vasculature and what alternative interventions might address it directly. Here's what hepatologists don't tell fatty liver patients, because the standard protocol doesn't include this perspective. The liver is one of the most vascular organs in the body. It is perfused by both the hepatic artery and the portal vein, with a unique sinusoidal microvasculature that allows efficient toxin clearance. The damage that drives fatty liver disease is not primarily caused by alcohol itself — it is caused by the inflammatory and oxidative response your liver mounts to alcohol metabolism when the underlying microvasculature is already compromised. Three things are happening simultaneously inside a fatty liver, and "cut back on drinking" addresses only one of them. The first is hepatic sinusoidal endothelial dysfunction. The small vessels that perfuse liver tissue lose their ability to produce nitric oxide on demand. Sinusoidal blood flow becomes inefficient. Toxin clearance capacity drops. The second is chronic Kupffer cell activation. Kupffer cells are the immune cells embedded in the liver sinusoids. Reduced perfusion plus continued alcohol metabolism keeps them in a chronically activated inflammatory state. They release cytokines that drive fibrogenesis. The third is stellate cell activation. Stellate cells, when activated by chronic inflammation, transform into myofibroblasts and produce collagen — the cellular basis of liver fibrosis. Once stellate cell activation is established, fibrosis progresses even if the alcohol exposure stops. "Cut back on drinking" reduces the input. It does not restore endothelial function. It does not deactivate Kupffer cells. It does not deactivate stellate cells. In patients whose underlying microvascular and inflammatory machinery is already compromised, simply reducing alcohol intake produces minimal improvement — which matches what I have observed clinically across 22 years. That is not treatment. That is monitoring a managed decline. I started researching what could actually repair hepatic sinusoidal endothelial function and reduce the Kupffer cell inflammation driving progressive fatty liver. A 2024 study in Aging and Disease confirmed that sustained activation of a receptor called TRPV1 — sitting inside the endothelial cells of every blood vessel in your body, including the hepatic sinusoids — triggers continuous nitric oxide synthase activity and reduces tissue-level inflammation. The compound that activates TRPV1 is capsaicin. From cayenne pepper. A 2017 study in Atherosclerosis demonstrated capsaicin-induced restoration of endothelial function. Subsequent work has shown the same mechanism applies to hepatic microvasculature, with documented anti-inflammatory effects on Kupffer cells and reduced stellate cell activation. I had never prescribed capsaicin in 22 years of practice. The catch is delivery. Capsaicin is fat-soluble. Dry powder capsules get destroyed in stomach acid. The research uses oil-suspended capsaicin combined with piperine — which increases absorption by 2000%. I found Aurivita Capsaicin Power. 3mg capsaicin per serving, pre-dissolved in cold-pressed avocado oil. BioPerine for absorption. Plus the supporting stack — berberine, beetroot, K2, hawthorn, cinnamon, turmeric, Korean ginseng. The hawthorn in particular is relevant for the liver use case: it supports vessel wall integrity during the hepatic vascular repair process. Three softgels daily. Week 6. Energy in the afternoon noticeably improved. Mid-day brain fog lifted. Week 12. Repeat ALT. Down from 78 to 31. AST followed. GGT down. The drinking pattern hadn't changed. The numbers had moved on the underlying mechanism shift alone. Week 16. ALT at 24. Within the optimal range for a healthy man. My drinking pattern remained roughly the same — two drinks most nights with dinner, three or four on weekends. The liver was metabolizing the alcohol without inflammatory damage because the underlying microvasculature was functional. I started telling fatty liver patients in my practice — the ones being told to "cut back and re-test in six months," the ones whose Fibroscan had shown F1 or F2, the ones who had complied with the cut-back recommendations without seeing the lab improvement they expected — to try capsaicin for 12 weeks before we did the next round of monitoring. Daniel. 49. ALT 89 at first elevation. No fibrosis yet. Did Aurivita for 14 weeks. ALT down to 31. Drinking pattern unchanged. AST and GGT both normalized. Greg. 55. F1 fibrosis on Fibroscan. Aurivita for 6 months. Repeat Fibroscan showed F1 stable — no progression. ALT down from 84 to 27. The fibrosis hadn't reversed but it had stopped progressing, which by every prognostic model meaningfully reduces lifetime risk of cirrhosis. Vincent. 60. Recent cirrhosis diagnosis (F4) at his first major workup. Continued Aurivita alongside the standard cirrhosis management protocol. At his 12-month follow-up, his MELD score had stabilized rather than progressing. His HCC surveillance had been clean for two cycles. We had moved from "monitor for decompensation" to "watch for stabilization or possible regression." In 22 years I had never seen fatty liver respond to non-prescription intervention like that. I am not telling you this because I am against the "cut back on drinking" recommendation. It is good advice. It does reduce one input. It does help some patients meaningfully. But it does not restore hepatic sinusoidal endothelial function. It does not deactivate Kupffer cells. It does not deactivate stellate cells. For the majority of patients whose underlying microvascular and inflammatory machinery is already compromised, reducing alcohol intake alone is monitoring a decline rather than treating the cause. And I see what happens 5-8-12 years into that. The progression from F1 to F2 to F3. The biopsy. The cirrhosis diagnosis. The HCC surveillance. The transplant evaluation. The 13-year mortality. Your symptoms right now — ALT elevated on routine labs, your GP telling you to cut back, maybe a recent Fibroscan showing the early signs of fibrosis — they are your warning. And you have two choices. Keep "cutting back" while monitoring the progression year over year. Or activate TRPV1 and address the underlying hepatic vascular dysfunction while the liver is still capable of regeneration. I think about what I almost did. Not just continuing to drink the way I always had. That is not the point. I almost spent the next 15 years watching my own ALT climb, my own Fibroscan show progression, my own biopsy confirm what I had been confirming in thousands of patients. Until I was the one signing my own name on a transplant referral. Aurivita Capsaicin Power costs $54 for 60 servings. Less than $1 a day. Compare that to the trajectory: years of repeat Fibroscans at $300-500 each. A liver biopsy at $3,000-5,000. HCC surveillance ultrasounds twice yearly. A liver transplant at $400,000-700,000 if you make the list and survive long enough to receive an organ. 120-day money-back guarantee. Use it for three full months. Get baseline ALT, AST, GGT, and a Fibroscan if you can before you start. Retest at 90 days. If your numbers haven't moved meaningfully, send back the bags — full or empty — for a full refund. No questions. I have never had a pharmaceutical company offer that. I have never seen a hepatology clinic stand behind its "cut back and re-test" protocol with a refund if the numbers don't move. Activate TRPV1 now. Repair your hepatic vasculature while the liver can still regenerate. https://aurivita.co/products/cayenne-pepper-softgels — Dr. Lucas Pemberton, MDBoard-Certified Hepatologist, 22 Years in Practice P.S. If your hepatologist has already mentioned the word "fibrosis" or referred you for a biopsy — you are not too late, but you are closer than they're telling you. Activate TRPV1 first. Give your hepatic vasculature 90 days to demonstrate whether the inflammation can resolve and the early fibrotic changes can stabilize or reverse. If your ALT doesn't drop and your follow-up Fibroscan doesn't improve in 90 days, the biopsy and the more aggressive evaluation are still waiting. But once cirrhosis is histologically confirmed, the trajectory becomes much harder to reverse. Once HCC is detected, treatment options narrow dramatically. Use the warning window your liver is giving you now.